Search results for "IMMUNOLOGY"

showing 10 items of 9651 documents

OP0062-HPR Efficacy of Tailored Exercise Therapy in Patients with Knee Osteoarthritis and Comorbidity: A Randomized Controlled Trial

2016

Background Exercise therapy is a key intervention in the management of knee osteoarthritis (OA). It is an effective intervention to improve physical functioning and reduce joint pain in patients with knee OA. Comorbidity, which is highly prevalent in OA, interferes with the application of exercise therapy and contributes to non-adherence to exercise therapy. Objectives To evaluate the efficacy and safety of tailored exercise therapy on physical functioning in patients with knee osteoarthritis (OA) and comorbidity Methods A randomized clinical controlled trial was performed, comparing comorbidity-adapted exercise therapy with a control intervention. The study was conducted in an outpatient r…

medicine.medical_specialtyWOMACbusiness.industryImmunologyOsteoarthritismedicine.diseaseComorbidityGeneral Biochemistry Genetics and Molecular Biologylaw.inventionRheumatologyRandomized controlled triallawRating scaleJoint painHeart failuremedicinePhysical therapyImmunology and Allergymedicine.symptomAdverse effectbusinessAnnals of the Rheumatic Diseases
researchProduct

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.

2021

The development of mepolizumab, an anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma, is an example of a clinical development program that evolved over time based on sound, basic scientific principles. Initial clinical data on the effects of mepolizumab on lung function in a general asthmatic population were disappointing. However, it became clear that mepolizumab may be more effective against other clinical endpoints, particularly asthma exacerbations, in patients with more severe disease. Furthermore, a developing understanding of asthma disease pathobiology led to the identification of an appropriate target population and predictive biomarker for mepolizumab t…

medicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationDiseaseAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineClinical endpointImmunology and AllergyMedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPrecision MedicineIntensive care medicineAdverse effecteducationComputingMilieux_MISCELLANEOUSAsthmaeducation.field_of_studybusiness.industrymedicine.diseaseAsthmaEosinophils030228 respiratory systemAsthma Control QuestionnairePersonalized medicinebusinessMepolizumabmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

Replacement Therapy for Surgery in FVII Deficiency: The Ster Experience Concerning 63 Interventions.

2009

Abstract Abstract 1290 Poster Board I-312 Background Excessive bleeding represents a major complication of surgical interventions, and its control is especially relevant in patients with Congenital Bleeding Disorders. In FVII deficiency, scanty data is available in surgery to guide treatment strategies. Methods The STER (Seven Treatment Evaluation Registry) is a multi-centre, prospective, observational, web-based registry providing the frame for an extensive and structured data collection. Results As of Dec. 2008, sixty-three surgical operations (36 “major” and 27 “minor”) were performed in 54 subjects (29 females and 25 males) with a FVII deficiency (31 previously symptomatic; 9 with FVIIc…

medicine.medical_specialtybiologyDosebusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryThrombosisEffective dose (pharmacology)SurgerySettore MED/15 - Malattie Del SangueDental extractionRecombinant factor VIIaHemostasisOrthopedic surgerymedicinebiology.proteinfactor VIIbusinessGynecological surgery
researchProduct

Incidence of the Factor V Leiden-mutation, Coagulation Inhibitor Deficiency, and Elevated Antiphospholipid-antibodies in Patients with Preeclampsia o…

2000

LETTER TO THE EDITORS-IN-CHIEF Incidence of the Factor V Leiden-mutation, Coagulation Inhibitor Deficiency, and Elevated Antiphospholipid-antibodies in Patients with Preeclampsia or HELLP–Syndrome Georg–Friedrich von Tempelhoff1, Lothar Heilmann1, Eberhard Spanuth1, Erich Kunzmann1 and Gerhard Hommel2 1Department of Obstetrics and Gynecology, City Hospital of Ruesselsheim and 2Institute for Medical Statistic and Documentation, University of Mainz, Germany.

medicine.medical_specialtybiologyHELLP syndromebusiness.industryFactor VHematologymedicine.diseaseGastroenterologyPreeclampsiaCoagulationObstetrics and gynaecologyAntiphospholipid syndromeInternal medicineImmunologymedicineFactor V Leidenbiology.proteinCoagulopathybusinessThrombosis Research
researchProduct

Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentratio…

2015

Background: OMA is an effective treatment option in SAA. However, little data are available on the long-term-efficacy oft the drug. Objective: To determine the long-term efficacy of OMA in respect to clinical parameters and IgE serum levels. Methods: This was a retrospective, open-label, uncontrolled, multi-center observational study according to the definition of non-interventional studies. 22 non-smoking patients (10 m, 12 f; mean age 47,9 yrs) with SAA were enrolled. Pat were treated with OMA up to for 4 years and total serum IgE levels were assessed at initiation of therapy, after 2-6 ms and 3-5 yrs. Data were recorded on standardized CRFs by the treating physician. Results: The average…

medicine.medical_specialtybiologybusiness.industryAllergic asthmaAtopic dermatitisOmalizumabImmunoglobulin Emedicine.diseaseGastroenterologyTreatment periodSerum igeFood allergyInternal medicineConcomitantImmunologybiology.proteinmedicinebusinessmedicine.drug5.3 Allergy and Immunology
researchProduct

ATHEROSCLEROSIS AND MARKERS OF INFLAMMATION IN PATIENTS WITH METABOLIC SYNDROME

2005

medicine.medical_specialtybiologybusiness.industryC-reactive proteinInflammationFibrinogenmedicine.diseaseTunica intimamedicine.anatomical_structureInternal medicineImmunologyInternal Medicinemedicinebiology.proteinCardiologyIn patientMyocardial infarctionmedicine.symptomMetabolic syndromebusinessNational Cholesterol Education Programmedicine.drug
researchProduct

Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis

2004

Objective To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A (Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behcet's disease (BD). Methods Included were 118 consecutive Italian BD patients followed over a 3-year period (1997–1999) who satisfied the International Study Group criteria for BD. The control group consisted of 132 healthy Italian blood donors. All BD patients and controls were genotyped by polymerase chain reaction and allele-specific restriction enzyme techniques for factor V Leiden and prothrombin gene G20210A polymorphisms. Results Vascular lesions were observed in 37 …

medicine.medical_specialtybiologybusiness.industryDeep veinImmunologyFactor VBehcet's diseasemedicine.diseaseGastroenterologyThrombophlebitisThrombosisVenous thrombosismedicine.anatomical_structureRheumatologyInternal medicineImmunologymedicinebiology.proteinFactor V LeidenImmunology and AllergyPharmacology (medical)cardiovascular diseasesbusinessAllele frequencyArthritis Care & Research
researchProduct

Intolerance to hydrolysed cow's milk proteins in infants: clinical characteristics and dietary treatment

2000

Summary Background Multiple food intolerance in infants, including intolerance to extensively hydrolysed proteins (HP), is often difficult to treat. However, few data have been reported on clinical outcome and dietary treatment of these patients. Aims To evaluate the clinical characteristics of patients with HP-intolerance and the longterm outcome of treatment with ass’ milk. Patients and Methods This study included 21 HP-intolerant infants (15 males, median age at diagnosis 2 months) treated with an ass’ milk-based diet and 70 cow’s milk (CM) intolerant infants (40 males, median age at diagnosis 3 months) treated with casein hydrolysate milk-based diet. All patients were followed-up for a …

medicine.medical_specialtybiologybusiness.industryDiet therapyImmunologyfood and beveragesImmunoglobulin Emedicine.diseaseGastroenterologyHydrolysateFood intoleranceEndocrinologyDietary treatmentIntolerancesInternal medicineCaseinbiology.proteinVomitingmedicineImmunology and Allergymedicine.symptombusinessClinical & Experimental Allergy
researchProduct

The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis

2003

Summary Objective: To determine the distribution of different antiphospholipid antibodies (APL-Ab) and their association with thrombosis in patients with autoimmune diseases. Methods: Clinical data and laboratory features of 30 patients with different autoimmune diseases with positive APL-Ab were retrospectively studied for a period of more than two years. Anti-cardiolipin (aCL), anti-phosphatidylserine (aPS) and anti-β2-glycoprotein I (aβ2-GPI) antibodies were determined by ELISA. Results: Autoantibodies that target only PS were detected in 53.3% (n=16) patients, aCL antibodies only were found in one patient (3,3%). In 43.3% (n=13), aPS were associated with elevated levels of aCL and/or aβ…

medicine.medical_specialtybiologybusiness.industryImmunologyAutoantibodyHematologySingle Centermedicine.diseaseThrombosisGastroenterologyInternal medicineImmunologymedicinebiology.proteinImmunology and AllergyIn patientAntibodybusinessImmunobiology
researchProduct